Table 1. Interval between HIV exposure and follow-up HIV tests for the 37 persons followed up after initially screening HIV-nonreactive in investigation of nosocomial HIV outbreak, Hangzhou,China, 2016–2017*.
| Potential contact |
Days between HIV exposure and follow-up HIV tests | |||||||
|---|---|---|---|---|---|---|---|---|
| 1st test |
2nd test |
3rd test |
4th test |
5th test |
6th test |
7th test |
8th test |
|
| Primary† | ||||||||
| Mrs. P0‡ | 24 | 29 | 45 | 68 | 103 | 130 | 191 | 464 |
| Q1 | 28 | 48 | 82 | |||||
| Q2 | 28 | 58 | 86 | 186 | ||||
| Q3 | 27 | 29 | 59 | 84 | 182 | |||
| Q4 | 28 | 58 | 86 | 192 | ||||
| Q5 | 28 | 45 | 86 | 192 | ||||
| Q6 | 28 | 56 | 94 | 188 | ||||
| Q7 | 27 | 28 | 57 | 99 | 211 | |||
| Q8 | 29 | 58 | 100 | 189 | ||||
| Q9 | 27 | 57 | 45 | 85 | ||||
| Q10 | 27 | 28 | 60 | 93 | 187 | |||
| Q11 | 28 | 64 | 106 | 202 | ||||
| Q12 | 29 | 55 | 83 | 185 | ||||
| Q13 | 27 | 29 | 58 | 89 | ||||
| Q14 | 27 | 35 | 62 | 92 | 199 | |||
| Q15 | 27 | 33 | 64 | 93 | 212 | |||
| Q16 | 27 | 45 | 93 | |||||
| Q17 | 27 | 33 | ||||||
| Q18 | 27 | 34 | 59 | 90 | 189 | |||
| Q19 | 27 | 33 | 63 | 91 | 187 | |||
| Q20 | 28 | 60 | 90 | 194 | ||||
| Q21 | 30 | 55 | 80 | 192 | ||||
| Q22 | 31 | 45 | 93 | 186 | ||||
| Q23 | 31 | 53 | 81 | 188 | ||||
| Q24 | 33 | 55 | 89 | 187 | ||||
| Q25 | 32 | 63 | 92 | 196 | ||||
| Q26 | 33 | 63 | 95 | 189 | ||||
| Q27 | 33 | 47 | 97 | 193 | ||||
| Q28 |
33 |
60 |
|
|
|
|
|
|
| Secondary§¶ | ||||||||
| P3’s husband | 7 | 30 | 57 | 97 | 182 | |||
| P4’s husband | 11 | 28 | 52 | 98 | 180 | |||
| P5’s husband | 2 | 18 | 25 | 32 | 60 | 196 | ||
| Infant P0 | 3 | 42 | 90 | 242 | ||||
| Infant P2 | 3 | 43 | ||||||
| Infant P4 | 1 | 44 | ||||||
*First HIV test was conducted using both nucleic acid testing and EIA. All subsequent HIV tests were conducted using EIA only. Blank cells indicate no further HIV test. EIA, enzyme immunoassay; LIT, lymphocyte immunotherapy; P, patient infected with HIV; Q, women who might have been exposed to HIV but were not infected. †Beginning of the time interval was counted from contaminated LIT at ZC Hospital on December 30, 2016. ‡Mrs. P0 is the wife of the index case-patient, P0. She is continuing to be followed once a year for at least 3 years since she discontinued antiretroviral therapy. Her most recent HIV test, on March 9, 2018, was again negative. §For husbands, beginning of the time interval was counted from the most recent sexual contact with the wife from the wife’s exposure on December 30, 2016, through the start of the investigation on January 25, 2017. Husbands received both serologic (4th-generation Ag/Ab EIA, Shanghai Kehua Bio-Engineering, Shanghai, China) and virologic testing (HIV-1 RNA, COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0, Roche, Branchburg, NJ, USA). ¶For infants, beginning of the time interval was counted as the date of birth. The first 3 HIV tests for infants were early infant diagnosis tests by a standard nucleic acid testing protocol. The fourth test for infant P0 was a 4th-generation Ag/Ab EIA.